The effect of endotoxin and endotoxin tolerance on inflammation induced by mycobacterial adjuvant

James (Jim) Rosenbaum, R. B. Mandell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peptidoglycan, the substance in mycobacteria thought to be responsible for inducing adjuvant arthritis, and endotoxin (lipopolysaccharide or LPS) share many inflammatory properties. Since repeated administration of LPS produces tolerance, i.e., resistance to the toxic and inflammatory effects of LPS, we tested whether LPS and/or LPS tolerance might influence inflammation due to mycobacterial adjuvant. Male Sprague-Dawley rats were injected with Escherichia coli LPS or saline intraperitoneally and then challenged with 100 μg killed Mycobacteria butyricum (adjuvant) in the footpad. A single dose of 100 μg LPS three or 24 hours before adjuvant markedly, but transiently, reduced the local footpad swelling that begins within hours of the adjuvant injection and histologically resembles a sterile abscess. Animals that received multiple doses of LPS and were therefore tolerant or animals that received LPS 72 hours before adjuvant demonstrated adjuvant-induced footpad swelling nearly equal to controls. The anti-inflammatory effect of LPS was transient since footpad swelling in all groups was nearly comparable six days after the adjuvant injection and LPS failed to inhibit consistently the arthritis that develops two or more weeks after adjuvant injection. These studies establish that LPS can markedly inhibit the prodrome of adjuvant arthritis (footpad swelling due to M. butyricum), that inhibition of this prodrome does not prevent the subsequent development of arthritis, and that LPS tolerance diminishes this anti-inflammatory effect of LPS.

Original languageEnglish (US)
Pages (from-to)293-301
Number of pages9
JournalYale Journal of Biology and Medicine
Volume56
Issue number4
StatePublished - 1983
Externally publishedYes

Fingerprint

Endotoxins
Swelling
Experimental Arthritis
Mycobacterium
Inflammation
Injections
Arthritis
Anti-Inflammatory Agents
Animals
Peptidoglycan
Poisons
Abscess
Sprague Dawley Rats
Lipopolysaccharides
Escherichia coli
Rats

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The effect of endotoxin and endotoxin tolerance on inflammation induced by mycobacterial adjuvant. / Rosenbaum, James (Jim); Mandell, R. B.

In: Yale Journal of Biology and Medicine, Vol. 56, No. 4, 1983, p. 293-301.

Research output: Contribution to journalArticle

@article{dff3a4c6ecf64e1b83d7fc99d82dbf08,
title = "The effect of endotoxin and endotoxin tolerance on inflammation induced by mycobacterial adjuvant",
abstract = "Peptidoglycan, the substance in mycobacteria thought to be responsible for inducing adjuvant arthritis, and endotoxin (lipopolysaccharide or LPS) share many inflammatory properties. Since repeated administration of LPS produces tolerance, i.e., resistance to the toxic and inflammatory effects of LPS, we tested whether LPS and/or LPS tolerance might influence inflammation due to mycobacterial adjuvant. Male Sprague-Dawley rats were injected with Escherichia coli LPS or saline intraperitoneally and then challenged with 100 μg killed Mycobacteria butyricum (adjuvant) in the footpad. A single dose of 100 μg LPS three or 24 hours before adjuvant markedly, but transiently, reduced the local footpad swelling that begins within hours of the adjuvant injection and histologically resembles a sterile abscess. Animals that received multiple doses of LPS and were therefore tolerant or animals that received LPS 72 hours before adjuvant demonstrated adjuvant-induced footpad swelling nearly equal to controls. The anti-inflammatory effect of LPS was transient since footpad swelling in all groups was nearly comparable six days after the adjuvant injection and LPS failed to inhibit consistently the arthritis that develops two or more weeks after adjuvant injection. These studies establish that LPS can markedly inhibit the prodrome of adjuvant arthritis (footpad swelling due to M. butyricum), that inhibition of this prodrome does not prevent the subsequent development of arthritis, and that LPS tolerance diminishes this anti-inflammatory effect of LPS.",
author = "Rosenbaum, {James (Jim)} and Mandell, {R. B.}",
year = "1983",
language = "English (US)",
volume = "56",
pages = "293--301",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - The effect of endotoxin and endotoxin tolerance on inflammation induced by mycobacterial adjuvant

AU - Rosenbaum, James (Jim)

AU - Mandell, R. B.

PY - 1983

Y1 - 1983

N2 - Peptidoglycan, the substance in mycobacteria thought to be responsible for inducing adjuvant arthritis, and endotoxin (lipopolysaccharide or LPS) share many inflammatory properties. Since repeated administration of LPS produces tolerance, i.e., resistance to the toxic and inflammatory effects of LPS, we tested whether LPS and/or LPS tolerance might influence inflammation due to mycobacterial adjuvant. Male Sprague-Dawley rats were injected with Escherichia coli LPS or saline intraperitoneally and then challenged with 100 μg killed Mycobacteria butyricum (adjuvant) in the footpad. A single dose of 100 μg LPS three or 24 hours before adjuvant markedly, but transiently, reduced the local footpad swelling that begins within hours of the adjuvant injection and histologically resembles a sterile abscess. Animals that received multiple doses of LPS and were therefore tolerant or animals that received LPS 72 hours before adjuvant demonstrated adjuvant-induced footpad swelling nearly equal to controls. The anti-inflammatory effect of LPS was transient since footpad swelling in all groups was nearly comparable six days after the adjuvant injection and LPS failed to inhibit consistently the arthritis that develops two or more weeks after adjuvant injection. These studies establish that LPS can markedly inhibit the prodrome of adjuvant arthritis (footpad swelling due to M. butyricum), that inhibition of this prodrome does not prevent the subsequent development of arthritis, and that LPS tolerance diminishes this anti-inflammatory effect of LPS.

AB - Peptidoglycan, the substance in mycobacteria thought to be responsible for inducing adjuvant arthritis, and endotoxin (lipopolysaccharide or LPS) share many inflammatory properties. Since repeated administration of LPS produces tolerance, i.e., resistance to the toxic and inflammatory effects of LPS, we tested whether LPS and/or LPS tolerance might influence inflammation due to mycobacterial adjuvant. Male Sprague-Dawley rats were injected with Escherichia coli LPS or saline intraperitoneally and then challenged with 100 μg killed Mycobacteria butyricum (adjuvant) in the footpad. A single dose of 100 μg LPS three or 24 hours before adjuvant markedly, but transiently, reduced the local footpad swelling that begins within hours of the adjuvant injection and histologically resembles a sterile abscess. Animals that received multiple doses of LPS and were therefore tolerant or animals that received LPS 72 hours before adjuvant demonstrated adjuvant-induced footpad swelling nearly equal to controls. The anti-inflammatory effect of LPS was transient since footpad swelling in all groups was nearly comparable six days after the adjuvant injection and LPS failed to inhibit consistently the arthritis that develops two or more weeks after adjuvant injection. These studies establish that LPS can markedly inhibit the prodrome of adjuvant arthritis (footpad swelling due to M. butyricum), that inhibition of this prodrome does not prevent the subsequent development of arthritis, and that LPS tolerance diminishes this anti-inflammatory effect of LPS.

UR - http://www.scopus.com/inward/record.url?scp=0021014838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021014838&partnerID=8YFLogxK

M3 - Article

C2 - 6670292

AN - SCOPUS:0021014838

VL - 56

SP - 293

EP - 301

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 4

ER -